Eritoran

[Anonymous]

The news is here. The question now is---how many field jobs will go? Thoughts?

 

[Anonymous]

"Eisai severe sepsis treatment eritoran (generic name; E5564) has failed to meet primary endpoint in a randomized, double-blind, placebo-controlled Phase II"

How many and where from will surely become evident by the end of this fiscal.

 

[Anonymous]

should be phase III

 

[Anonymous]

Is onc safe with halaven launch? I could interview with another company but prefer Eisai right now and halaven.

 

[Anonymous]

Not a shock if you have followed this drug class the last year and listened to LC at the POA.

 

[Anonymous]

Is onc safe with halaven launch? I could interview with another company but prefer Eisai right now and halaven.

Same situation here. Resume going out today. I would do the same. Just because you get an offer doesn't mean that you have to take it.

 

[Anonymous]

Is onc safe with halaven launch? I could interview with another company but prefer Eisai right now and halaven.

Onc is NOT safe. Everyone on the table.

 

[Anonymous]

Onc is NOT safe. Everyone on the table.

How will they decide? Forced ranking? I would think onc is relatively safe?

 

[Anonymous]

How will they decide? Forced ranking? I would think onc is relatively safe?

No one is safe. Watch the shit storm that happens in the next few weeks. You ain't seen nothing yet!

 

[Anonymous]

How will they decide? Forced ranking? I would think onc is relatively safe?

Onc is NOT safe.

Everyone is on the table to meet their needs. Not your needs.

 

[Anonymous]

No one is safe. Watch the shit storm that happens in the next few weeks. You ain't seen nothing yet!

You shouldn't say things like this unless you have proof.

 

[Anonymous]

If you think you are safe because you call on CLINICS in ONC instead of Hospitals you are crazy!! As above post said....It will be a shit storm and after all said and done...you may still have a job but it may not be in the arena you are in currently. GOOD LUCK TO ALL!!!!

 

[Anonymous]

If past downsizing predicts future downsizing, then I would say the ones at the higher pay scale may have some concern. The days of overpaying for DM's and reps is over.

 

[Anonymous]

If past downsizing predicts future downsizing, then I would say the ones at the higher pay scale may have some concern. The days of overpaying for DM's and reps is over.

Eisai is looking into the cuts. Start with each region and the highest paid reps will go first, DM will be given the option either be cut or take pay cut and become a rep. 50% is the goal.

 

[Anonymous]

U R Phucked

 

[Anonymous]

If past downsizing predicts future downsizing, then I would say the ones at the higher pay scale may have some concern. The days of overpaying for DM's and reps is over.

I call BS. They would be dumb to get rid of the experienced reps if they want Halaven to continue growth after launch.

 

[Anonymous]

Eisai is looking into the cuts. Start with each region and the highest paid reps will go first, DM will be given the option either be cut or take pay cut and become a rep. 50% is the goal.

I don't believe this. They aren't getting rid of all DMs. Why would they get rid of high paying reps also? In Onc they have the relationships in accounts. If they are so blind to this, good luck to Eisai.

 

[Anonymous]

You guys don't really get it do you?

This is game over. Eritoran was the plug for the hole to be left by LOE of Aricept and declining AcipHex revenue.

Now there is no plug.

You really don't get it if you are debating who is more at risk. They need to cut and they need to cut fast. None of us are "safe." Game over.

 

[Anonymous]

Eisai is looking into the cuts. Start with each region and the highest paid reps will go first, DM will be given the option either be cut or take pay cut and become a rep. 50% is the goal.

Do paycut apply to OB, SS, and LC?

 

[Anonymous]

"Eisai Co. said its experimental drug to treat severe sepsis failed to save more lives than a placebo in a final-stage study."

Perhaps they will pay millions for the marketing rights to promote placebo.